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Abstract
Background: Nothing is known about the epidemiology and resistance mechanisms of extended-spectrum
ß-lactamase-producing Enterobacteriaceae (ESBL-PE) in Burkina Faso. The objective of this study was to determine
ESBL-PE prevalence and to characterize ESBL genes in Burkina Faso.
Methods: During 2 months (June-July 2014), 1602 clinical samples were sent for bacteriologic investigations to the
microbiology laboratories of the tree main hospitals of Burkina Faso. Isolates were identified by mass spectrometry
using a matrix-assisted laser desorption ionization-time of flight (MALDI-TOF) BioTyper. Antibiotic susceptibility was
tested using the disk diffusion method on Müller-Hinton agar. The different ESBL genes in potential ESBL-producing
isolates were detected by PCR and double stranded DNA sequencing. Escherichia coli phylogenetic groups were
determined using a PCR-based method.
Results: ESBL-PE frequency was 58 % (179 strains among the 308 Enterobacteriaceae isolates identified in the collected
samples; 45 % in outpatients and 70 % in hospitalized patients). The CTX-M-1 group was dominant (94 %, CTX-M-15
enzyme), followed by the CTX-M-9 group (4 %). ESBL producers were more often found in E. coli (67.5 %) and Klebsiella
pneumoniae (26 %) isolates. E. coli isolates (n = 202; 60 % of all Enterobacteriaceae samples) were distributed in eight
phylogenetic groups (A = 49, B1 = 15, B2 = 43, C = 22, Clade I = 7, D = 37, F = 13 and 16 unknown); 22 strains belonged
to the sequence type ST131. No association between a specific strain and ESBL production was detected.
Conclusions: This report shows the alarming spread of ESBL genes in Burkina Faso. Public health efforts should focus
on education (population and healthcare professionals), surveillance and promotion of correct and restricted antibiotic
use to limit their dissemination.
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Background
The emergence and spread of Multidrug Resistant (MDR)
bacteria are major public health threats. Particularly,
bacteria that produce extended-spectrum ß-lactamases
(ESBL) are of great concern because their resistance to
penicillins and narrow- and extended-spectrum cephalo-
sporins reduces considerably the treatment options [1].
ESBL genes originally evolved from the ß-lactamase TEM-
1, TEM-2 and SHV-1 genes through mutations of the
amino acids surrounding the active site and were mainly
detected in nosocomial pathogens [2]. However, during
the past decade, the rapid and massive spread of CTX-M-
type ESBLs has been described worldwide. This has
considerably changed their epidemiology because they
combine the expansion of mobile genetic elements with
specific clonal dissemination [3]. Furthermore, such
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plasmids typically carry resistance genes also to other
drugs, such as aminoglycosides and fluoroquinolones [2].
Recent studies suggest that CTX-M-type ESBL- producing
Enterobacteriaceae (ESBL-PE) are endemic in most coun-
tries of Europe, Asia and South America, with high rates
of CTX-M-type ESBL-producers particularly among
Escherichia coli (30 to 90 %) and Klebsiella pneumoniae
(10 to 60 %) [4, 5]. Despite these public health concerns,
little is known about ESBL diffusion in Africa. ESBL-PE
rates between 8.8 and 13.1 % were reported in South
Africa [6] and an alarmingly high proportion of ESBL-PE
(49.3 %) was found among clinical isolates from Ghana
[7]. Conversely, no information is available on the
epidemiology of ESBL-producing pathogens in hospital or
community settings in Burkina Faso, a low-income
country close to Ghana. Therefore, the aim of the present
study was to estimate ESBL occurrence in clinical samples
from hospitalized and non-hospitalized patients and to
characterize the ESBL genes as well as the genetic back-
ground of the identified E. coli strains.
Methods
Study setting
During 2 months (June–July 2014), all consecutive clinical
samples sent to the microbiology laboratories of the three
main hospitals of Burkina were investigated. Specifically:
1. Yalgado Ouedraogo Teaching Hospital (CHU-YO)
is the largest medical institution located in
Ouagadougou, the capital city with a population of
about 2 million inhabitants. This hospital has 716
beds and intensive care units that are used for
surgical, medical and trauma emergencies. Annually,
more than 20,000 inpatients (children and adults)
are admitted among 126,000 consultations.
2. Souro Sanou Teaching Hospital (CHU-SS) is the
major healthcare and referral centre for the
southern and western regions of Burkina Faso. It has
521 beds distributed in different specialized
(medicine, surgery, gynaecology obstetric and
paediatric) acute care units. The annual number of
hospitalizations ranges from 15,000 to 20,000
patients among 108,000 consultations.
3. Charles de Gaulle Paediatric Teaching Hospital
(CHUP-CDG) is the referral paediatric hospital in
Ouagadougou with 120 beds. About 6000 children
are seen each year and 5000 are hospitalized. The
microbiology laboratory also receives samples from
adult outpatients.
Specimen collection, identification and antimicrobial
susceptibility testing
In June and July 2014 (CHU-SS and CHUP-CDG) and
July 2014 (CHU-YO), 1602 clinical samples were sent to
the three microbiology laboratories for bacteriologic
investigations (CHU-YO: n = 521, CHU-SS: n = 528 and
CHUP-CDG: n = 553). Bacterial cultures could be
obtained only from 584 of these samples (mainly be-
cause of poor pre-analytical sample handling) and they
included 308 Enterobacteriaceae isolates. Enterobacteria-
ceae isolates were recovered from urine (n = 185), pus
(n = 56), aspirates from various anatomic sites (n = 38),
stool (n = 16), blood (n = 8), vaginal swabs (n = 3) and
cerebrospinal fluid samples (n = 2). The remaining 276
isolates included Gram positive cocci (Staphylococcus
spp and Streptococcus spp) and Gram negative bacilli (e.g.,
Pseudomonas aeruginosa and Acinetobacter baumanii).
Species identification was performed by matrix-assisted
laser desorption ionization-time of flight (MALDI-TOF)
mass spectrometry (Bruker Daltonics, Bremen, Germany).
Antimicrobial susceptibility was tested with the disk diffu-
sion method on Müller-Hinton agar. The following an-
tibiotics were tested: penicillins (amoxicillin, amoxicillin-
clavulanic acid, piperacillin, piperacillin-tazobactam, ticar-
cillin, ticarcillin-clavulanic acid), monobactam (aztreonam),
oxacephem (moxalactam), extended-spectrum cephalo-
sporins (cefepime, cefotaxime, cefpirome, cefpodoxime,
cefoxitin, ceftazidime, cephalotin), carbapenems (imipe-
nem), aminoglycosides (amikacin, gentamicin, netilmicin
and tobramycin), quinolones (nalidixic acid, ciprofloxacin,
levofloxacin, ofloxacin) fosfomycin, chloramphenicol, tetra-
cycline and trimethoprim-sulfamethoxazole. Results were
interpreted according to the European Committee on
Antimicrobial Susceptibility Testing (EUCAST) clin-
ical breakpoints (Version 5.0) (http://www.eucast.org/
clinical_breakpoints/). ESBL production was detected
by using the combined double-disk synergy method
[8]. In case of high-level cephalosporinase production,
the combined double-disk synergy test was performed
using cloxacillin-supplemented medium. Ertapenem
minimal inhibitory concentrations (MIC), determined
using the Etest (bioMerieux), were determined for all
isolates.
Molecular identification of ESBL genes
DNA was extracted from one single colony for each isolate
in a final volume of 100 μL of distilled water by incubation
at 95 °C for 10 min followed by a centrifugation step. The
presence of blaCTX-M (CTX-M group 1, 2, 8, 9 and 25),
blaTEM, blaSHV and blaOXA-like genes was assessed by
multiplex PCR according to a previously published
method [9]. DNA from reference blaCTX-M, blaTEM,
blaSHV and blaOXA-like-positive strains was used as
positive control. PCR products were visualized after
electrophoresis on 1.5 % agarose gels containing eth-
idium bromide at 100 V for 80 min. A 100 bp DNA
ladder (Promega, USA) was used as a marker size.
PCR products were purified using the ExoSAP-IT
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purification kit (GE Healthcare, Piscataway, NJ, USA)
and sequenced bidirectionally on a 3100 ABI Prism
Genetic Analyzer (Applied Biosystems). Nucleotide se-
quence alignment and analyses were performed online
using the BLAST program available at the National
Center for Biotechnology Information web page
http:// www.ncbi.nlm.nih.gov.
PCR detection of Escherichia coli phylogroups and ST131
E. coli phylogenetic grouping was performed using the
PCR-based method described by Clermont and al. [10].
For strains assigned to the B2 phylogenetic group, the
sequence type (ST) 131 was determined using a PCR
method specific for the O25-b serotype with primers
that target the pabB and trpA genes, as previously
described [11].
Statistical analysis
Statistical analysis was performed with Epi Info, version
3.5.3 [Centers for Disease Control and Prevention (CDC),
Atlanta, GA, USA]. Associations between demographic
variables (sex, site of infection and age) and infection by
ESBL-PEs were analysed by using odds ratio and a multi-
nomial logistic regression model, when appropriate. A
value of p < 0.05 was considered to be statistically
significant.
Results
Occurrence of ESBL-producing enterobacteriaceae
During the study period, 308 different enterobacterial
isolates were recovered from 158 hospitalized and 150
non-hospitalized patients (Table 1). The mean age of
these patients was 29.7 ± 24.6 years and the sex ratio 1.4;
118 patients (38 %) were younger than 15. Among these
308 isolates, 179 (58 %) were identified as potential
ESBL-PEs by antimicrobial susceptibility testing. PCR
analysis confirmed that they all carried ESBL genes
(Table 1). Considering the isolate origin, ESBL-PE preva-
lence was of 65 % (42/65) at CHU-YO, 59 % (84/142) at
CHU-SS and 52 % (53/101) at CHUP-CDG. Moreover,
ESBL-PEs were found in 45 % of outpatients and 70 % of
hospitalized patients (p < 0.001). In hospitalized patients,
no demographic factor was significantly associated with
ESBL-PE occurrence (p > 0.05) (Table 1). Conversely in out-
patients, the ESBL-PE prevalence was significantly higher
among patients older than 65 years of age (Odd Ratio
[OR] = 6.4, 95 % CI = 0.47–86.34; p < 0.001). ESBL-PE
rate was also significantly higher in male than female
outpatients (OR = 4.59) and in urinary samples (59 of 119;
50 %) (Table 1). Species identification showed that the 179
ESBL-PEs included 121 (67.5 %) E. coli, 46 (26 %) K. pneu-
moniae, 7 (4 %) Enterobacter cloacae, 2 (1 %) Providencia
stuartii, 1 (0.5 %) Enterobacter aerogenes, 1 (0.5 %) Citro-
bacter freundi and 1 (0.5 %) Morganella morgannii species
(Table 2). The highest proportion of ESBL-PEs was found
Table 1 Demographic characteristics and source of the bacterial isolates
Outpatients (n = 150) Inpatients (n = 158)
Variable ESBL-positive ESBL-negative Odds Ratio (95 % CI) P-value ESBL-positive ESBL-negative Odds Ratio (95 % CI) P-value
(n = 68) (n = 82) (n = 111) (n = 47)
Sex <0.001 0.724
F (n = 129) 16 48 1 47 18 1
M (n = 179) 52 34 4.59 (2.14–9.84) 64 29 0.85 (0.42–1.70)
Source of isolates 0.019 0.139
Urine sample (n–185) 59 60 1 48 18 1
Pus (n = 56) 06 07 0.87 (0.28–2.75) 32 11 1.09 (0.46–2.61)
Aspirate (n = 38) 02 03 0.68 (0.11–4.20) 24 09 1.00 (0.39–2.56)
Othera (n = 29) 01 12 0.08 (0.01–0.67) 07 09 0.29 (0.09–0.90)
Age <0.001 0.607
≤28 days 01 02 1 09 04 1
>28 days–1 year 01 08 0.20 (0.01–4.72) 07 04 0.78 (0.14–4.27)
>1–5 years 02 15 0.31 (0.02–5.19) 06 06 0.44 (0.09–2.28)
>5–15 years 04 07 1.14 (0.08–16.95) 30 12 1.11 (0.29–4.31)
>15–65 years 44 45 1.96 (0.17–22.35) 49 19 1.15 (0.32–4.17)
>65 years 16 05 6.40 (0.47–86.34) 10 02 2.22 (0.33–15.18)
Abbreviations: CI confidence interval, ESBL extended-spectrum beta-lactamase, F females, M males, n number
aOther: stool, cerebrospinal fluid, blood samples and high vaginal swabs
Ouedraogo et al. BMC Infectious Diseases  (2016) 16:326 Page 3 of 9
in blood samples (6/8, 75 %). Moreover, within each spe-
cies, the fraction of ESBL producers was highest among
Morganella morgannii isolates (100 %), followed by K.
pneumoniae (66 %) and E. coli (60 %) (Table 2). The 129
non-ESBL-PEs included E. coli (81/2002, 40 %), K. pneu-
moniae (24/70, 34 %) Enterobacter cloacae (6/13, 46 %),
Providencia stuartii (4/6, 66 %) Enterobacter aerogenes (2/
3, 77 %) Citrobacter freundi (2/3, 66 %), Salmonella spp
(3/3, 100 %), Proteus mirabilis (5/5, 100 %) and Leclercia
adecarboxylata (1/1) species.
Antibiotic susceptibility patterns
The susceptibility pattern of ESBL producing (n = 179)
and non-producing (n = 129) Enterobacteriaceae isolates
is shown in Fig. 1. ESBL-PE isolates were more resistant
to the other tested antibiotics than non-producers: cotri-
moxazole (45 % vs 5 %), gentamicin (89 % vs 27.5 %),
tobramycin (86 % vs 9 %), netilmicin (88 % vs 12 %),
ciprofloxacin (80 % vs 12 %), ofloxacin (70 % vs 7 %) and
levofloxacin (82 % vs 27 %) (p < 0.05). None of the
collected Enterobacteriaceae isolates was resistant to
Table 2 Prevalence of ESBL-producing isolates among the different Enterobacteriaceae species identified in our samples
Distribution of ESBL-producing isolates in samples (%)
Species Within species Total Urine Stool Blood Pus Aspirates HVS CSF
(%) (n = 185) (n = 16) (n = 18) (n = 56 (n = 38) (n = 3) (n = 2)
Escherichia coli 121/202 (60 %) 67.5 % 67/114 0/15 0 29/39 23/31 2/2 0/1
Klebsiella pneumonia 46/70 (66 %) 26 % 32/51 0 5/6 6/8 3/4 0/1 0
Enterobacter cloacae 7/13 (54 %) 4 % 6/10 0 0 1/3 0 0 0
Enterobacter aerogenes 1/3 (33 %) 0.5 % 1/2 0 0 0 0/1 0 0
Citrobacter koseri 0/1 – 0 0 0 0 0/1 0 0
Citrobacter freundi 1/3 (33 %) 0.5 % 1 /2 0 0 0/1 0 0 0
Proteus mirabilis 0/5 – 0/4 0 0 0/1 0 0 0
Providencia stuartii 2/6 (33 %) 1 % 0/1 0 1/1 1/3 0/1 0 0
Salmonella spp 0/3 – 0 0/1 0/1 0 0 0 0/1
Morganella morgannii 1/1 (100 %) 0.5 % 0 0 0 1/1 0 0 0
Leclercia adecarboxylata 0/1 – 0/1 0 0 0 0 0 0
Total (%) 179/308 (58 %) 100 % 107/185 0/16 6/8 38/56 26/38 2/3 0/2
Abbreviations: CSF cerebrospinal fluid, ESBL extended-spectrum beta-lactamase, HVS high vaginal swab, n = number
Fig. 1 Results of the antibiotic susceptibility test for the 179 ESBL-producing (ESBL-PE) and the 129 non-ESBL-producing (NON ESBL-PE) Enterobacteriaceae
isolates. The histogram shows the percentage of ESBL-PE and NON ESBL-PE isolates that were susceptible to each tested antibiotic compound. Y axis:
Antibiotic susceptibility (%)
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imipenem. Four isolates had high ertapenem MCI.
Additional investigations showed that these four isolates
carried blaOXA181 (47).
Molecular characterization of ESBL and other ß-lactamase
genes
Most ESBL-PE isolates (94 %) were identified as
CTX-M group 1 producers because all of them car-
ried the blaCTX-M-15 gene. CTX-M group 9 producers
represented only 4 % of all ESBL-PEs (blaCTX-M-14 was
detected in three isolates and blaCTX-M-27 in five samples
(Table 3). The blaSHV-12 gene was detected in two isolates.
The ESBL genes were detected alone or in association
with one to three other ß-lactamase genes: blaOXA-1,
blaSHV-1 and blaTEM-1. While blaCTX-M-15 was found in all
the different enterobacterial species, blaCTX-M-14 was de-
tected only in E. coli samples (n = 3), blaCTX-M-27 in E. coli
(n = 2), K. pneumoniae (n = 1) and E. cloacae (n = 1) iso-
lates, and blaSHV-12 in one E. coli and one K. pneumoniae
sample (Table 3).
Table 3 Characterization of genes encoding beta lactamases in the 179 ESBL-producer isolates
Outpatients (n = 68) Inpatients (n = 111)
Isolates (n) Hospital (n) ESBL Type Other ß-lactamases ESBL Types Other ß-lactamases
Escherichia coli (121) CHU-YO (37) CTX-M-15 (1) OXA-1(1) CTX-M-14 (1) SHV-1, TEM −1 (1)
CTX-M-15 (2) SHV-1 (2) CTX-M-14 (1) TEM-1 (1)
CTX-M-15 (1) TEM-1 (1) CTX-M-15 (3) TEM-1, OXA-1 (3)
CTX-M-15 (1) – CTX-M-15 (7) TEM-1(7)
– – CTX-M-15 (3) SHV-1 (3)
– – CTX-M-15 (12) OXA-1 (12)
– – CTX-M-15 (3) –
– – CTX-M-27 (2) TEM-1 (2)
CHUSS (52) CTX-M-15 (3) SHV-1, OXA-1 (3) CTX-M-15 (1) SHV-1, OXA-1 (1)
CTX-M-15 (1) TEM-1, OXA-1 (1) CTX-M-15 (1) TEM-1, OXA-1 (1)
CTX-M-15 (2) TEM-1 (2) CTX-M-15 (1) TEM-1 (1)
CTX-M-15 (27) OXA-1 (27) CTX-M-15 (15) OXA-1 (15)
SHV-12 (1) – – –
CHUP-CDG (32) CTX-M-15 (1) OXA-1 (1) CTX-M-14 (2) TEM-1, OXA-1 (2)
CTX-M-15 (4) TEM-1(4) CTX-M-15 (8) TEM-1, OXA-1 (8)
CTX-M-27 (1) OXA-1, TEM-1(1) CTX-M-15 (10) TEM-1(10)
– – CTX-M-15 (6) OXA-1 (6)
Klebsiella pneumonia (46) CHU-YO (5) CTX-M-15(1) TEM-1, OXA-1(1) CTX-M-15 (1) SHV-1, OXA-1, TEM-1 (1)
SHV-12 (1) – CTX-M-15 (2) OXA-1 (2)
CHUSS (24) CTX-M-15(1) SHV-1, OXA-1, TEM-1(1) CTX-M-15(3) SHV-1, OXA-1, TEM-1(3)
CTX-M-15(2) SHV-1, OXA-1, (2) CTX-M-15(2) SHV-1, OXA-1 (2)
CTX-M-15(3) SHV-1, TEM-1 (3) CTX-M-15(2) OXA-1, TEM-1 (2)
CTX-M-15(5) OXA-1 (5) CTX-M15 (2) OXA-1 (2)
CTX-M-15(1) TEM-1(1) CTX-M–15(1) –
CTX-M-15(2) SHV-1 (2) – –
CHUP-CDG (17) CTX-M-15 (2) OXA-1 (2) CTX-M-15 (3) OXA-1(3)
– – CTX-M-15 (5) EM-1, OXA-1 (5)
– – CTX-M-15(4) SHV-1, TEM-1(4)
– – CTX-M-15(2) SHV-11
– – CTX-M-27(1) SHV-1(1)
Other strains (12) CTX-M-15(2) OXA-1, TEM-1 (2) CTX-M-15 (5) OXA-1, TEM-1
CTX-M-15 (2) TEM-1, SHV-1 (2) CTX-M-15 (1) SHV-11(1)
CTX-M-27 (1) OXA-1 (1) CTXM-15 (1) –
Abbreviations: N number
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Escherichia coli phylogenetic groups and sequence type 131
The phylogenetic group analysis revealed diversity in
both ESBL-producing and non-producing E. coli isolates
(n = 202). Specifically, E. coli isolates belonged to eight
different phylogenetic groups (A = 49, B1 = 15, B2 = 43,
C = 22, Clade I = 7, D = 37 F = 13) and 16 could not be
classified according to Clermont and al. method [10].
These 16 isolates might represent a new phylogenetic
group. Phylogenetic group A was more represented
among ESBL-producers (31 of 121; 26 %), followed by
group D and B2 (for both: 26 of 121; 21.5 %). Non-ESBL
producers belonged mainly to the phylogenetic groups A
and B2 (18 and 17 of 81, respectively; 21 %). Moreover,
the ST131 sequence type was detected in 16 ESBL-
producers and in six non-producers (Table 4).
Discussion
In this study, we investigated the frequency of ESBL
production by Enterobacteriaceae isolates from clinical
samples sent to the three main hospitals of Burkina Faso
in June and July 2014. Overall, 58 % of these isolates
were ESBL-PEs. This is much higher than the rates
reported in Europe [12, 13] and in other African coun-
tries: Algeria (17.7–31.4 %), Egypt (42.9 %) [14] and
Ghana (49.4 %) [7]. Lack of antibiotic surveillance may
have contributed to increasing the ESBL-PE problem
that certainly has been present in Burkina Faso for a
long time. Indeed, it has been shown that in countries
with limited resources where hygiene is poor and antibi-
otics are misused, the absence of anti-microbial surveil-
lance programmes increases the risk of multi-resistance
development by bacteria in hospitals and in the commu-
nity [15–17]. We found that blood cultures had the
highest proportion of ESBL-PE isolates. This differs from
the results of a recent literature review on ESBL-PE
prevalence in Africa [18] showing a significantly lower
proportion of ESBL-PE in blood cultures than in other
specimens. This discrepancy is certainly explained by the
small number of enterobacterial strains (eight of which
six were ESBL-PEs) recovered from blood samples.
Indeed, 107 ESBL-PEs were identified in urine samples
(107/185, 58 %), a prevalence similar to what reported in
previous studies [7, 19–21]. ESBL producers were more
often found in E. coli (67 %) and K. pneumoniae (26 %)
isolates, in agreement with previous works showing that
these two species are the predominant ESBL-producers
worldwide [2, 22]. ESBL-producing E. coli is considered
to be responsible for hospital- and community-acquired
infections, while ESBL-producing K. pneumoniae is con-
sidered mainly a nosocomial pathogen [2, 22]. In agree-
ment, we identified ESBL-producing K. pneumoniae
most frequently in samples from hospitalized patients.
ESBL-PE prevalence differed considerably between out-
patients and inpatients (45 % vs. 70 %: p < 0.001). More
than two thirds of enterobacterial infections in hospital-
ized patients were thus caused by an ESBL-PE. In
Burkina Faso, patients are usually hospitalized only in
the case of very severe symptoms and after a long and
empiric antibiotic therapy. These factors could explain
this alarmingly high resistance level in hospitalized pa-
tients and also in outpatients (45 % compared with 7.5 %
of community-acquired infections in Morocco [23] and
11.7 % in Nigeria) [24]. In outpatients, ESBL-PE
frequency was significantly higher in isolates from older
patients (more than 65 years of age, [OR] = 6.4, 95 %
CI = 0.47–86.34). These results are in agreement with
the study by Colodner and al. [3] showing that elderly
patients present a higher antibiotic pressure and more
underlying diseases, two significant risk factors for in-
fection by ESBL producers [25]. In addition, ESBL-PE
rate was significantly higher in male outpatients (OR =
4.59, 95 % CI = 2.14–9.84) and the urinary tract was the
most frequent source (59 of 119, 50 %). The possible
explanation may be that complicated urinary tract in-
fections are more frequent in elderly men than elderly
women [26].
Table 4 Phylogenetic group assignment of the 202 E. coli strains subdivided based on the detection or not of ESBL genes
ESBL-Positive (n = 121) ESBL-Negative (n = 81)
A B1 B2 C Clade I D F Unknown ST131 A B1 B2 C Clade I D F Unknown ST131
Hospital (number of samples)
CHU-YO (55)
Outpatients (16) 0 0 3 0 0 2 0 0 1 0 0 1 6 0 0 0 4 0
Inpatients (39) 9 2 4 6 0 5 6 0 3 0 0 3 0 0 2 0 2 1
CHU-SS (90)
Outpatients (59) 6 1 11 4 2 8 1 0 8 7 2 7 4 1 3 2 0 4
Inpatients (31) 7 1 5 1 0 3 1 1 4 2 2 1 1 1 0 1 3 0
CHUP-CDG (57)
Outpatients (20) 0 1 0 0 0 2 2 1 0 7 2 3 0 0 1 0 1 1
Inpatients (37) 9 2 3 0 3 6 0 3 0 2 2 2 0 0 5 0 1 0
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In this study most ESBL-PEs were resistant to multiple
drugs, especially to fluoroquinolones, aminoglycosides,
cotrimoxazole and tetracycline, as described in previous
studies [27–29]. This level of multi-resistance could lead
to potential therapeutic impasses. Indeed, more than three
quarters of ESBL-PE isolates were resistant to fluoroquino-
lones and aminoglycosides (but for amikacin), thus com-
promising the choice of antibiotic treatment, especially for
outpatients with urinary tract infections. Moreover alter-
native antimicrobial agents, such as amikacin, fosfomycin
and imipenem, are very expensive and difficult to obtain in
Burkina Faso. These alarming results should act as an im-
petus for the establishment of antibiotic control policies.
Indeed, currently, there is no restriction in the use of anti-
biotics in Burkina Faso. Antibiotics can be purchased over
the counter without medical prescription. Patients may
buy only a few tablets of an antibiotic because of limited
money availability. Moreover, patients may begin an anti-
microbial regimen and stop it when they feel better, before
the end of the treatment, to save the remaining tablets for
another time.
Finally, we found that 94 % of ESBL-PEs carried the
blaCTX-M-15 gene. In the last decade, CTX-M enzymes,
particularly CTX-M-15, have emerged worldwide and
are the most prevalent in Europe, America and Asia
[30–36]. Moreover, eight strains were CTX-M group 9
producers (blaCTX-M-27 in five and blaCTX-M-14 in three).
These genes have been previously detected in E. coli
isolates in Kenya [37] and in Egypt [38]. Nevertheless,
the blaCTX-M-15 gene remains dominant in the African
continent: 59 % of ESBL-PE in South Africa [34], 83 %
in Mali [39], 91 % in Tunisia [40] and 96 % in Cameroon
[41]. The blaSHV-12 gene (detected in one E. coli and one
K. pneumoniae sample) has emerged in recent years and
has been also detected in different Enterobacteriaceae
isolates in the previously quoted studies in African coun-
tries [34, 38–41].
The phylogenetic group assignment of the 202 E. coli iso-
lated showed a high diversity in both populations (out-pa-
tients and in-patients) without any association between a
specific strain and ESBL production. This indicates that the
high frequency of ESBL carriage is not caused by the epi-
demic spread of a single resistant clone. This contrasts with
previous studies in which the dissemination of CTX-M-15-
producing isolates was associated with the spread of the
ST131 E. coli strain belonging to phylogenetic group B2
[42–44]. Indeed, in the present study, most isolates were
assigned to the commensal groups A (49/202, 24 %) and
B2 (43/202, 21 %). Only 13 % (16/121) of ESBL-producers
and 7 % (6/81) of non ESBL-producers belonged to the
ST131 clone. Moreover, some ESBL-producing E. coli iso-
lated from urine, pus and blood samples belonged to three
phylogenetic groups associated with CTX-M-15 dissemin-
ation: the virulent extra-intestinal group D (26/121) [45]
and groups C (11/121) and F (10/121), usually detected in
urinary tract infections [46]. This important genetic diver-
sity among isolates suggests that the high rate of ESBL pro-
duction and associated resistance are more likely caused
by the diffusion of plasmids carrying antibiotic resistance
genes than to cross-transmission between patients. The
maintenance of these plasmids was probably favoured by
antibiotic pressure. Further investigations, including mul-
tilocus sequence typing and plasmid characterization, are
needed to complete this study.
Conclusions
In summary, this first survey shows an alarmingly high
frequency of multi-resistant ESBL-PEs among clinical
isolates in Burkina Faso. The analysis of the resistance
genes highlighted an important dissemination of blaCTX-
M-15 without clonal dissemination, suggesting a strong
antibiotic selection pressure in hospital and community
settings. Public health efforts should focus on educating
the population and healthcare professionals about the
proper use of antibiotics to halt/limit the spread of
multi-resistant bacteria.
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